<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03293381</url>
  </required_header>
  <id_info>
    <org_study_id>826102</org_study_id>
    <nct_id>NCT03293381</nct_id>
  </id_info>
  <brief_title>Electrogram-Guided Myocardial Advanced Phenotyping</brief_title>
  <acronym>eMAP</acronym>
  <official_title>Electrogram-Guided Myocardial Advanced Phenotyping (The eMAP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fluoroscopy guided EMB and EAM guided EMB on all patients meeting existing guidelines for&#xD;
      biopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-Ischemic Cardiomyopathy (NICM) is a common cause of heart failure (HF) and death. NICM is&#xD;
      a heterogeneous entity, and specific etiologies are infrequently identified. In part due to&#xD;
      limited disease characterization, specific treatments are lacking for most of the different&#xD;
      underlying causes of NICM. Depending on the cohort, 30-70 percent of patients with new-onset&#xD;
      NICM develop persistent systolic dysfunction despite guideline-directed medical therapy, and&#xD;
      these patients have high rates of subsequent morbidity and resource utilization.&#xD;
&#xD;
      Current guidelines support the use of endomyocardial biopsy (EMB) in patients with both&#xD;
      new-onset and persistent cardiomyopathy. However, EMB is underutilized in these populations&#xD;
      due to its low diagnostic yield. A combination of sampling error resulting from standard&#xD;
      fluoroscopy-guided EMB in disease entities with patchy myocardial involvement and rudimentary&#xD;
      tissue phenotyping of the specimens which are obtained contribute to this low diagnostic&#xD;
      yield. In recent years, there has been increasing interest in the use of electro-anatomic&#xD;
      mapping (EAM) to help identify areas of myocardium with discrete pathology based on&#xD;
      abnormalities in intra-cardiac electrogram voltage and morphologies. Therefore, the primary&#xD;
      objective of this protocol is to provide definitive evidence that EAM-guided biopsy leads to&#xD;
      a superior diagnostic yield compared with conventional fluoroscopy-guided biopsy in patients&#xD;
      with new-onset and persistent NICM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fluoroscopy guided EMB and EAM guided EMB on all patients meeting existing guidelines for biopsy.</measure>
    <time_frame>November 2018</time_frame>
    <description>Additional biopsies</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-ischemic Cardiomyopathy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>additional biopsies</intervention_name>
    <description>additional biopsies</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with New onset NICM that are scheduled for a biopsy as part of their clinical care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years&#xD;
&#xD;
          2. New onset NICM as defined by the presence of left ventricular dysfunction (LVEF &lt; 45%&#xD;
             by echocardiography and/or MRI), with symptoms or signs of HF (dyspnea, orthopnea,&#xD;
             edema, ascites, rales or pulmonary vascular congestion on chest radiography) of less&#xD;
             than 3 months in duration.&#xD;
&#xD;
          3. Persistent recent onset NICM as defined by the LVEF and signs/symptoms in #2 above&#xD;
             with persistence of the LVEF &lt; 45% despite evidence-based treatment for HF with&#xD;
             reduced LVEF for 2 to 6 months.&#xD;
&#xD;
          4. Willingness to provide informed consent&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior diagnosis of HF or documented LVEF &lt; 45% more than 6 months prior to enrollment.&#xD;
&#xD;
          2. Coronary artery disease, either by history or as determined by coronary angiography&#xD;
             demonstrating hemodynamically significant lesions deemed sufficient to potentially&#xD;
             contribute to left ventricular dysfunction.&#xD;
&#xD;
          3. Ongoing hemodynamically significant arrhythmias deemed to be an independent cause of&#xD;
             HF decompensation&#xD;
&#xD;
          4. Constrictive pericarditis or tamponade&#xD;
&#xD;
          5. Complex congenital heart disease&#xD;
&#xD;
          6. History of malignancy with treatment by anthracyclines or other known cardiotoxic&#xD;
             chemotherapeutic agents&#xD;
&#xD;
          7. More than mild aortic or mitral stenosis&#xD;
&#xD;
          8. Intrinsic (prolapse, rheumatic) valve disease with severe mitral, aortic or tricuspid&#xD;
             regurgitation&#xD;
&#xD;
          9. Primary hypertrophic cardiomyopathy&#xD;
&#xD;
         10. Untreated thyroid disease&#xD;
&#xD;
         11. Severe nutritional deficiency&#xD;
&#xD;
         12. Severe uncontrolled hypertension&#xD;
&#xD;
         13. Sepsis, active infection (excluding cystitis) or other comorbidity driving the HF&#xD;
             decompensation&#xD;
&#xD;
         14. History of cardiac transplantation&#xD;
&#xD;
         15. Acute or chronic severe liver disease as evidenced by any of the following:&#xD;
             encephalopathy, variceal bleeding, INR &gt; 1.5 in the absence of anticoagulation&#xD;
             treatment&#xD;
&#xD;
         16. Inability to comply with planned study procedures&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis Marchlinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

